Floatz logo

Lederfolin

Gall Bladder Cancer

University of PisaDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

30 Active assets in the Gall Bladder Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Lisata Therapeutics, Inc.
Phase 2BBB
Capecitabine
Merck Sharp & Dohme LLC
Phase 3BB
Eloxatin
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Sevoflurane
Tokyo Medical and Dental University
Phase 4BB
Epirubicin
Merck Sharp & Dohme LLC
Phase 2BB

View all 50 →

Same molecule, other indications

Lederfolin is also rated in:

colon carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
colorectal cancerDormant
D
Indicative ·
30 / 100
View asset →
biliary tract cancerDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →